JP2016503778A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503778A5
JP2016503778A5 JP2015548640A JP2015548640A JP2016503778A5 JP 2016503778 A5 JP2016503778 A5 JP 2016503778A5 JP 2015548640 A JP2015548640 A JP 2015548640A JP 2015548640 A JP2015548640 A JP 2015548640A JP 2016503778 A5 JP2016503778 A5 JP 2016503778A5
Authority
JP
Japan
Prior art keywords
substituted
compound according
compound
branched
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503778A (ja
JP6515035B2 (ja
Filing date
Publication date
Priority claimed from FR1203548A external-priority patent/FR3000065A1/fr
Application filed filed Critical
Publication of JP2016503778A publication Critical patent/JP2016503778A/ja
Publication of JP2016503778A5 publication Critical patent/JP2016503778A5/ja
Application granted granted Critical
Publication of JP6515035B2 publication Critical patent/JP6515035B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015548640A 2012-12-21 2013-12-20 マイコバクテリアに対して活性な抗生物質の活性を増強する飽和窒素及びn−アシル化複素環 Active JP6515035B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR12/03548 2012-12-21
FR1203548A FR3000065A1 (fr) 2012-12-21 2012-12-21 Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
PCT/EP2013/077732 WO2014096378A1 (fr) 2012-12-21 2013-12-20 Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries

Publications (3)

Publication Number Publication Date
JP2016503778A JP2016503778A (ja) 2016-02-08
JP2016503778A5 true JP2016503778A5 (cg-RX-API-DMAC7.html) 2017-02-02
JP6515035B2 JP6515035B2 (ja) 2019-05-15

Family

ID=48521019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548640A Active JP6515035B2 (ja) 2012-12-21 2013-12-20 マイコバクテリアに対して活性な抗生物質の活性を増強する飽和窒素及びn−アシル化複素環

Country Status (23)

Country Link
US (1) US9957249B2 (cg-RX-API-DMAC7.html)
EP (1) EP2935212B1 (cg-RX-API-DMAC7.html)
JP (1) JP6515035B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150138152A (cg-RX-API-DMAC7.html)
CN (1) CN104955804B (cg-RX-API-DMAC7.html)
AU (1) AU2013366503B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015014279A2 (cg-RX-API-DMAC7.html)
CA (1) CA2895606A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015001640A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150319A (cg-RX-API-DMAC7.html)
EA (1) EA028076B1 (cg-RX-API-DMAC7.html)
FR (1) FR3000065A1 (cg-RX-API-DMAC7.html)
GE (1) GEP20186857B (cg-RX-API-DMAC7.html)
IL (1) IL239504B (cg-RX-API-DMAC7.html)
MA (1) MA38275B1 (cg-RX-API-DMAC7.html)
MX (1) MX2015008029A (cg-RX-API-DMAC7.html)
PE (1) PE20151327A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501427A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201504492UA (cg-RX-API-DMAC7.html)
TN (1) TN2015000202A1 (cg-RX-API-DMAC7.html)
UA (1) UA117922C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014096378A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503719B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EA201590943A1 (ru) 2012-12-21 2016-01-29 Алиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
FR3000064A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
EA031892B1 (ru) 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2
ES2899365T3 (es) * 2017-08-16 2022-03-11 Glaxosmithkline Ip Dev Ltd Compuestos novedosos
AU2018317805B2 (en) * 2017-08-16 2021-04-15 BioVersys AG Novel compounds
WO2019034702A1 (en) * 2017-08-16 2019-02-21 Glaxosmithkline Intellectual Property Development Limited NEW COMPOUNDS
RU2767542C1 (ru) * 2021-05-24 2022-03-17 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
EP1118612A1 (en) * 2000-01-21 2001-07-25 Universita Degli Studi di Firenze Piperazine derivatives possesing nootropic activity
TW593556B (en) 2002-12-27 2004-06-21 Ind Tech Res Inst Dichroic dye, composition thereof, and liquid crystal composition and liquid-crystal display element containing the same
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
FR2903405B1 (fr) * 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
TW200938203A (en) * 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
US9050295B2 (en) 2007-12-21 2015-06-09 Eth Zurich Composition for treatment of tuberculosis
EP2321274A1 (en) * 2008-07-08 2011-05-18 Boehringer Ingelheim International GmbH Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors
EP2350053B1 (en) * 2008-10-17 2013-12-11 Whitehead Institute For Biomedical Research Modulators of MTOR Complexes
FR2939135B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
US8912329B2 (en) 2009-06-25 2014-12-16 BioVersys AG Composition for treatment of tuberculosis
KR101179508B1 (ko) * 2010-06-24 2012-09-07 한국과학기술연구원 1,6-이치환-3-아미노-4,5,6,7-테트라하이드로-1H-피라졸로[3,4-c]피리딘-7-온 화합물 및 이 화합물의 제조방법
WO2013060744A2 (en) 2011-10-25 2013-05-02 Universite De Droit Et De La Sante De Lille 2 Compounds having an ethr inhibiting activity - use of said compounds as drugs - pharmaceutical composition and product containing said compounds
JP2015516436A (ja) * 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Nampt阻害薬
SI2875003T1 (sl) 2012-07-20 2017-03-31 Bayer Pharma Aktiengesellschaft Nove 5-aminotetrahidrokinolin-2-karboksilne kisline in njihova uporaba
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes

Similar Documents

Publication Publication Date Title
JP2016503778A5 (cg-RX-API-DMAC7.html)
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2015537020A5 (cg-RX-API-DMAC7.html)
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
JP2016514159A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2011529054A5 (cg-RX-API-DMAC7.html)
JP2016501250A5 (cg-RX-API-DMAC7.html)
JP2015516427A5 (cg-RX-API-DMAC7.html)
JP2011513305A5 (cg-RX-API-DMAC7.html)
JP2015024998A5 (cg-RX-API-DMAC7.html)
JP2015520769A5 (cg-RX-API-DMAC7.html)
JP2016516043A5 (cg-RX-API-DMAC7.html)
JP2013531031A5 (cg-RX-API-DMAC7.html)
JP2013056919A5 (cg-RX-API-DMAC7.html)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2014502988A5 (cg-RX-API-DMAC7.html)
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
JP2015521195A5 (cg-RX-API-DMAC7.html)
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
JP2020505440A5 (cg-RX-API-DMAC7.html)
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
AR108712A1 (es) (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis
MX385203B (es) Compuestos y métodos para tratar infecciones bacterianas.